All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How has AML treatment in elderly people changed in 2021?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Tapan M. Kadia, MD Anderson Cancer Center, Houston, US. We asked, How has acute myeloid leukemia treatment in elderly people changed in 2021?

How has AML treatment in elderly people changed in 2021?

Kadia begins by highlighting the treatment challenges for elderly patients, such as higher frequency of comorbidities, organ dysfunction, and frailty. He outlines therapies such as venetoclax and hypomethylating agents, which demonstrate a good safety profile. Finally, he discusses current studies that are further investigating the role of NGS and cytogenetic analysis in selecting treatment options and therapy combinations.

 

Share: